OPTImal Treatment of Sinus VENOSUS Defect
Recruiting
N/A
Interventional Study
Sinus Venosus Defect
Congenital Heart Disease
Sinus Venosus Atrial Septum Defect
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 12 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- Centre Chirurgical Marie Lannelongue · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Sinus venosus defect (SVD) accounts for 10% of atrial septal defects and is characterized by an anomalous pulmonary venous return in the superior vena cava associated with a high situated atrial septal defect. Since 2013, transcatheter correction of this congenital heart disease has emerged as a new treatment option. The procedure involves placement of a covered stent in the superior vena cava tha…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* from 12 years of age
* SVD with right ventricular end-diastolic volume dilatation (RV EDV) on imaging (echocardiography and/or MRI), defined by the guidelines as RV EDV greater than 112mL/m2 for women and 121 mL/m2 for men.
* With an indication for atrial septal defect correct…
Contacts